ImmunityBio, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Richard Gerald Adcock
- Full Time Employees
- 688
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3530 John Hopkins Court San Diego CA United States of America 92121
- IPO Date
- Jul 28, 2015
- CIK
- 0001326110
- Website
- immunitybio.com
- Similar Companies
- Business
- ImmunityBio, Inc. (NASDAQ: IBRX) develops next-generation immunotherapies that bolster the natural immune system to fight cancers and infectious diseases; its platforms include antibody-cytokine fusion proteins such as the FDA-approved Anktiva (N-803/nogapendekin alfa inbakicept-pmln), an IL-15 superagonist used in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ; vaccine vectors encompassing DNA, RNA, and adenovirus-based technologies for personalized cancer vaccines and HPV-related therapies; and cell therapies featuring NK-92-derived natural killer cells like PD-L1 t-haNK, alongside T-cell therapies and macrophage activators that target solid tumors (pancreatic, lung, colorectal), liquid tumors, HIV, and Lynch syndrome-associated cancers. The company, founded in 2014 and headquartered in San Diego, California, with additional operations in Culver City, California, and Morrisville, North Carolina, operates as a vertically integrated, commercial-stage biotechnology firm conducting internal cGMP manufacturing and a robust clinical pipeline across multiple phases and indications in collaboration with the National Cancer Institute, Serum Institute of India Private Limited, and BeiGene, Ltd. Recent developments include FDA approval of Anktiva in April 2024, an $80 million equity financing via registered direct offering with institutional investors in July 2025 to support operations and clinical trials, and a partnership with nCartes announced in November 2024 to automate clinical trial data processes.
Company News
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?
ImmunityBio: None Of The Moonshots Is Priced In
Canada Pension Plan Investment Board Acquires Shares of 70,200 ImmunityBio, Inc. $IBRX
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
Bell & Brown Wealth Advisors LLC Makes New $657,000 Investment in ImmunityBio, Inc. $IBRX
Bank of America Corp DE Increases Position in ImmunityBio, Inc. $IBRX
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)
ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
ImmunityBio: A Long-Term Bull Case Worth Watching
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?